Aurobindo Pharma Receives USFDA Approval for Perampanel Epilepsy Tablets
Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market Perampanel Tablets in multiple strengths. The drug treats partial-onset seizures and primary generalized tonic-clonic seizures in patients aged four and older. The product, equivalent to Catalyst Pharmaceuticals' Fycompa Tablets, will be produced at Aurobindo's subsidiary and is expected to launch in the third quarter of fiscal year 2027. The market size is estimated at $67 million for the year ending August 2026. Aurobindo now holds 599 ANDA approvals from the USFDA.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 41/100.
Outlets measured: news18, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 3 Oct, 11:50 am. Other outlets followed.